ãã€ãªãã¯ãããžãŒäŒæ¥ã§ãããŠãã€ãããã»ã»ã©ãã¥ãŒãã£ã¯ã¹ã»ã³ãŒãã¬ãŒã·ã§ã³ã¯ãç±³åœããã³äžçäžã§ãæ
¢æ§çŸæ£ãçåœãè
ããçŸæ£ãæ£ãæ£è
ã®æºããããŠããªãå»çããŒãºã«å¯Ÿå¿ãã補åã®éçºãšåååã«åãçµãã§ããŸããå瀟ã®åžè²©æ²»çè¬ã«ã¯ãèºåèæ§èºé«è¡å§ç (PAH) æ£è
ã®éåé¢é£çç¶ã軜æžããããã®ç®äžããã³éèå
æäžçšã®ããã¹ã¿ãµã€ã¯ãªã³é¡äŒŒäœãã¬ããã¹ããã«ã®æ³šå
¥è£œå€ã§ãã RemodulinãPAH æ£è
ã®éåèœåãé«ããããã®ãã¬ããã¹ããã«ã®åžå
¥è£œå€ã§ãã TyvasoãPAH æ£è
ã®éåèœåãé«ããããã®ãã¬ããã¹ããã«ã®é å€å€åœ¢ã§ãã Orenitramãé«ãªã¹ã¯ç¥çµèœçްèè
«ã®æ²»çã®ããã®ã¢ãã¯ããŒãã«æäœã§ãã Unituxinãããã³ PAH æ£è
ã®éåèœåãé«ããããã®çµå£ PDE-5 é»å®³å€ã§ãã Adcirca ããããŸããå瀟ã¯ãŸããPAH æ²»ççšã® OreniProãRemoProãTyvaso DPIãTrevyentãRalinepagãAurora-GTãæ°ç®¡æ¯èºç°åœ¢æçæ²»ççšã® Unexisome ã®éçºãåçå»çãç°çš®ç§»æ€ãäœå€èºçæµãªã©ã®ããŸããŸãªèåšç§»æ€é¢é£æè¡ã®ç ç©¶éçºãããã³ãã®ä»ã®çŸæ£ã®æ²»çè¬ã®éçºã«ãåãçµãã§ããŸããå瀟ã¯ãRemodulin ã®åã蟌ã¿åã·ã¹ãã ã®éçºãšåååã«é¢ã㊠Medtronic, Inc. ãšããã®æ³šå
¥ã»ã³ã¿ãŒã§åã蟌ã¿åãã³ãã®è©°ãæ¿ããæäŸããã«é¢ã㊠Caremark, LLC ãšãRemodulin ã®ç®äžæäžçšã®åäœ¿ãæšãŠã·ã¹ãã ã®éçºã«é¢ã㊠DEKA Research & Development Corp. ãšããã¬ããã¹ããã«åžå
¥ç²æ«ãš Dreamboat ããã€ã¹ã®éçºãšã©ã€ã»ã³ã¹ã«é¢ã㊠MannKind Corporation ãšãPAH æ²»ççšã® ralinepag ã®éçºã«é¢ã㊠Arena Pharmaceuticals, Inc. ãšã©ã€ã»ã³ã¹å¥çŽããã³ååå¥çŽãçµãã§ããŸããå瀟㯠1996 幎ã«èšç«ãããã¡ãªãŒã©ã³ãå·ã·ã«ããŒã¹ããªã³ã°ã«æ¬ç€Ÿã眮ããŠããŸãã